Nurix Therapeutics Inc (NRIX) Stock Price, Quote & News

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK)...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 660 5320

Fax: 415-525-4200

Website: www.nurixtx.com

Address:

1600 Sierra Point Parkway, Brisbane, United States

stjernerogvann Mar. 11 at 5:52 PM

$SLS by comparison, $NRIX has a $1.6B market cap, is only in P2, and is going after a similarly sized leukemia indication (CLL.) $SLS is farther along and seems to have objective evidence that GPS works so it should be at least 1.5x $NRIX market cap, IMO.

1 · Reply

LongTrainRunning Mar. 6 at 7:41 PM

$NRIX This could be our last chance to load up at these prices before EHA. Once the weak sellers exit and volume picks up things will look brighter.

0 · Reply

LongTrainRunning Mar. 4 at 7:42 PM

$NRIX it's been a gradual decline since ASH in December, which isn't a big surprise. But EHA is quickly approaching in June. We're basically at the halfway point and we should start to see a meaningful run up in the next month or two. I'm betting that EHA will give us more positive data that are 6 months more mature than ASH 2025. I'm hoping that we revisit the highs we saw in December before we even see new data. Good luck longs!

0 · Reply

oaksapollo Mar. 3 at 2:12 AM

$NRIX You guys see the Roche fenebrutinib data in MS? If a BTK inhibitor works that well, a BTK degrader could be a game changer in MS.

1 · Reply

oaksapollo Feb. 24 at 3:41 AM

$NRIX Gilead was probably the most logical acquirer of Nurix. Seems impossible now, at least in the near term, due to their $8B buy of Arcellx. Guess we have to play the long game now.

1 · Reply

OfficialStocktwitsUser Feb. 22 at 6:31 PM

$NRIX RSI: 41.55, MACD: -0.6694 Vol: 1.14, MA20: 16.76, MA50: 18.00 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

oaksapollo Feb. 18 at 3:12 AM

$NRIX nice to see Baker Bros continue to increase their position

1 · Reply

oaksapollo Feb. 16 at 5:02 PM

$NRIX What do you guys think is the likelihood of Nurix being acquired? Seems like it would be an absolutely perfect strategic fit for Gilead. I feel like if anyone were going to do it, now would be the time - bexo has been significantly de-risked, but an approved product is still a few years away so market cap is quite reasonable.

1 · Reply

LongTrainRunning Feb. 12 at 9:50 PM

$NRIX bought some more today. Hopefully we'll level out soon. March is the midpoint between ASH 2025 and EHA 2026. So it might keep drifting down until the run-up begins in April or May. Tremendous value right now.

1 · Reply

LongTrainRunning Feb. 5 at 9:35 PM

$NRIX I just want to say you're welcome to anyone looking to buy because I loaded up in the $16.50 - $17.50 range. So of course it continues to go down 🤣. I'm not sweating it. Just annoyed. I think we'll be north of $30 by end of year after ASH.

1 · Reply

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

Jan 16, 2026, 5:13 AM EST - 2 months ago

Nurix Therapeutics: Why This Company Could Double In Value?

Jan 12, 2026, 11:15 PM EST - 2 months ago

Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:42 AM EST - 2 months ago

Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside

Jan 12, 2026, 7:00 AM EST - 2 months ago

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Jan 5, 2026, 7:00 AM EST - 2 months ago

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 4:27 AM EST - 3 months ago

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript

Dec 8, 2025, 8:00 AM EST - 3 months ago

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

$Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition$

Dec 6, 2025, 9:30 AM EST - 3 months ago

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Dec 1, 2025, 7:00 AM EST - 3 months ago

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 25, 2025, 7:00 AM EST - 3 months ago

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 7:00 AM EST - 4 months ago

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nov 7, 2025, 9:00 AM EST - 4 months ago

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nov 3, 2025, 9:00 AM EST - 4 months ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2025, 7:00 AM EDT - 4 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Oct 27, 2025, 7:00 AM EDT - 4 months ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Oct 22, 2025, 6:53 PM EDT - 5 months ago

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript

Oct 22, 2025, 7:20 AM EDT - 5 months ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

$Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia$

Oct 22, 2025, 6:00 AM EDT - 5 months ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Oct 18, 2025, 3:00 AM EDT - 5 months ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Oct 11, 2025, 8:13 AM EDT - 5 months ago

Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones

Oct 9, 2025, 4:01 PM EDT - 5 months ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Sep 17, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Sep 12, 2025, 9:56 AM EDT - 6 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 12, 2025, 9:43 AM EDT - 6 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Sep 11, 2025, 3:14 AM EDT - 6 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 10, 2025, 9:42 AM EDT - 6 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Jul 13, 2025, 8:30 AM EDT - 8 months ago

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

Jul 9, 2025, 4:01 PM EDT - 8 months ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 7, 2025, 7:00 AM EDT - 8 months ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jun 13, 2025, 4:01 PM EDT - 9 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$

Jun 12, 2025, 7:00 AM EDT - 9 months ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 6, 2025, 7:00 AM EDT - 10 months ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 2, 2025, 7:00 AM EDT - 10 months ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

May 28, 2025, 7:00 AM EDT - 10 months ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 10 months ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:30 AM EDT - 10 months ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Apr 28, 2025, 4:00 PM EDT - 11 months ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 25, 2025, 1:00 PM EDT - 11 months ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 17, 2025, 5:07 PM EDT - 11 months ago

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Apr 17, 2025, 7:00 AM EDT - 11 months ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 8, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 13, 2025, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Feb 4, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 4:00 PM EST - 1 year ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 22, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Jan 9, 2025, 8:44 AM EST - 1 year ago

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

stjernerogvann Mar. 11 at 5:52 PM

1 · Reply

LongTrainRunning Mar. 6 at 7:41 PM

$NRIX This could be our last chance to load up at these prices before EHA. Once the weak sellers exit and volume picks up things will look brighter.

0 · Reply

LongTrainRunning Mar. 4 at 7:42 PM

0 · Reply

oaksapollo Mar. 3 at 2:12 AM

$NRIX You guys see the Roche fenebrutinib data in MS? If a BTK inhibitor works that well, a BTK degrader could be a game changer in MS.

1 · Reply

oaksapollo Feb. 24 at 3:41 AM

$NRIX Gilead was probably the most logical acquirer of Nurix. Seems impossible now, at least in the near term, due to their $8B buy of Arcellx. Guess we have to play the long game now.

1 · Reply

OfficialStocktwitsUser Feb. 22 at 6:31 PM

0 · Reply

oaksapollo Feb. 18 at 3:12 AM

$NRIX nice to see Baker Bros continue to increase their position

1 · Reply

oaksapollo Feb. 16 at 5:02 PM

1 · Reply

LongTrainRunning Feb. 12 at 9:50 PM

1 · Reply

LongTrainRunning Feb. 5 at 9:35 PM

1 · Reply

VolckerRuleX Feb. 4 at 1:43 PM

$NRIX is a life sciences tools company providing cell and gene therapy manufacturing services; demand is strong but the competitive landscape is intensifying as capacity grows.

0 · Reply

LongTrainRunning Jan. 30 at 3:41 PM

$NRIX might be premature but I loaded up this morning. Now I’m holding steady through EHA in June.

0 · Reply

oaksapollo Jan. 28 at 10:20 PM

$NRIX new paper just out https://www.biorxiv.org/content/10.64898/2026.01.22.701125v1.full.pdf IMO, the CBL-B program is the sleeper program. Everyone is focused on BTK, but I think in the long run (5-10 years), the CBL-B drug will be the biggie. Anti-CD3/anti-CD28 is a very strong stimulus. The fact that they can rev up these T cells well beyond anti-CD3/CD28 is impressive.

0 · Reply

d_risk Jan. 28 at 10:12 PM

$NRIX - Nurix Therapeutics Inc. Common stock - 10K - Updated Risk Factors NRIX’s 2026 10-K sharpens focus on mounting cash burn and funding needs for early-stage bexobrutideg and zelebrudomide, higher clinical and platform spend, novel degrader science risk, IP and litigation exposure, complex global regulation and pricing pressure, third-party and supply-chain dependencies, and heightened stock, governance, and operational growing pains. #Biotechnology #SupplyChain #IntellectualProperty #FinancialRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/NRIX/10-K/2026-01-28

0 · Reply

oaksapollo Jan. 28 at 7:42 PM

$NRIX this stock is bipolar.

1 · Reply

OfficialStocktwitsUser Jan. 28 at 3:08 PM

$NRIX RSI: 50.66, MACD: 0.2761 Vol: 0.56, MA20: 18.69, MA50: 18.03 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

revuelto Jan. 27 at 6:40 PM

$NRIX looks good✌️

0 · Reply

TradeTracs Jan. 27 at 1:53 PM

🚀Today's Top Stocks🚀 $NRIX - Tight price action $JAZZ - Strong relative strength $VRT - Daily chart inverse head and shoulders With the market coming into highs, I am waiting to see if we reject at this level before making any moves. $SPY $QQQ

0 · Reply

oaksapollo Jan. 26 at 5:07 PM

$NRIX added another 1000 shares here. It's been consolidating at this level for a while now and the bids for March $20, 21, 22 calls are telling me it's about to move higher.

1 · Reply

tievLeaf Jan. 21 at 3:45 PM

$QSI Nuff said, just see this post by ARK recently and tell me if you think this price range of $1 FOR QUANTUM-SI ain't undervalued as fuck. Just FYI, they are categorizing Nurix Therapeutics at the same category with QSI and Nurix is currently at $19. $ILMN $SLS $FEMY $NRIX

2 · Reply

oaksapollo Jan. 9 at 6:52 PM

$NRIX Was able to sell 10 Feb $25 covered calls today for $0.70. Seems like a great deal with pretty bullish pricing. However, the last time I sold $18 covered calls when the stock was at $10 they actually got exercised. I won't be too upset if it happens again. Still own 97.5% of my position free and clear.

1 · Reply

Market Cap	1.55B
Revenue (ttm)	83.98M
Net Income (ttm)	-264.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-314.91%
Debt to Equity Ratio	0.00

Volume	757,300
Avg Vol	1,053,184
Day's Range	N/A - N/A
Shares Out	102.84M
Stochastic %K	24%
Beta	1.96
Analysts	Strong Sell
Price Target	$29.00